

Exosome Diagnostics develops and commercializes blood-based cancer molecular diagnostics for patient stratification and disease monitoring. Among its major competitors, Exosome Diagnostics is ranked in 9th place for NPS while 23andMe is 1st, and Guardant Health is 2nd.